RESPONSE RATES TO SOFOSBUVIR AND DACLATASVIR IN CHRONIC HEPATITIS C PATIENTS

Main Article Content

Ali Azmat
Maliha Sheikh
Saad Azim
Muniba Saeed
Saeed Abbasi

Abstract

Objectives: To evaluate the effectiveness of daclatasvir and sofosbuvir in treating hepatitis C genotype 3a patients
Material and Methods This was a prospective interventional study .Consecutive non probability sampling technique
was followed . It was carried out in Department of Medicine KRL hospital Islamabad, Pakistan from February 2017 to
June 2018. This study included 80 patients who were infected with hepatitis C virus. Age ranged from 17-83 years.
Amongst them 70 were treatment naive while 10 has received Pegylated Interferon and ribavirin in the past. Of treatment
experienced 7 out of 10 patients had achieved SVR. Before starting treatment baseline laboratory tests were done
and recorded. Quantitative PCR for HCV RNA and Genotyping was done. All patients received treatment for 3 months.
Patients had a follow up every two weeks. Quantitative PCR for HCV RNA was performed at the end of treatment,3
months and 6 months after completion of treatment. Response rates were recorded. Data was analysed using statistical
package for social sciences version 17 (SPSS 17).
Results: Out of 80 patients54 (67%) were females and 26 (33%) were males. All patients were of genotype 3a. 70
patients (87%) had never experienced treatment before and 10 patients(13%) had previous treatment with pegylated
interferon and ribavirin. End of treatment response was observed in 98.8% of patients while sustained virological response(
SVR 12) and SVR 24 was observed in 96.25% of patients. Side effects mainly constitutional symptoms occured
in about one tenth of patients.
Conclusion: Directly acting antiviral drugs(DAA) have improved outlook in hepatitis C treatment while concomitantly
reducing the duration of treatment and has high safety profile.

Article Details

Section
Articles

Most read articles by the same author(s)